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Hematological disorders are considered risk factors for acute and
late complications in patients with acute coronary syndrome (ACS)
undergoing percutaneous coronary intervention (PCI). In particu-
lar, thrombocytopenia (TP) is associated with a higher risk for
bleeding in patients with ACS treated with antithrombotic
therapies1 and has been shown to be a predictor of in-hospital
mortality in patients undergoing PCI.1 In acute myeloid leukemia
(AML), replacement of normal bone marrow with leukemic cells
causes anemia, TP, and abnormal white blood cells count.
Therefore, these patients represent a challenge for clinicians if
PCI strategy for ACS is required. Several trials demonstrated that,
in patients with acquired TP, the incidence of bleedings is reduced
with bivalirudin treatment, a thrombin-speciﬁc anticoagulant, as
compared with heparin plus glycoprotein (GP) IIb/IIIa inhibitor
use.1,2 Moreover, patients undergoing PCI with stent deployment
require a mandatory dual antiplatelet therapy (DAT) to prevent the
risk of stent thrombosis, myocardial infarction and death.3,4
Accordingly, PCI guidelines indicate the DAT course ranging
from 2–4 weeks after plain-old balloon angioplasty, 4–6 weeks
after bare-metal stent or up to 6–12 months after drug-eluting
stent.5 Here, we report the case of a patient with severe AML who
developed chest pain as a result of ACS-non-ST elevation
myocardial infarction (NSTEMI).
A 69-year-old male patient was admitted to our coronary care
unit with chest pain and ST depression on ECG in V1-V4 leads,
history was notable for hypertension, dyslipidemia and smoking
habitus. Blood pressure was 80/50mmHg and heart rate was110
bpm. At echocardiographic examination, left ventricle appeared
mildly dilated and ipokinetic with ejection fraction (EF) of 35%.
Regional abnormalities were described; in particular, ipokinesia of
the interventricular septum and the apex and akinesia of the
inferior wall. Serum levels of troponin I were increased(3.5 ng/ml).
Haemochrome revealed anemia (Hb: 9.9 g/dl, RBC: 2.89 106/ml),
low white blood cells count (WBC: 1.33 103/ml) and TP (93 103/ml)
leading to a strong suspect of leukemia. A pharmacological
therapy with ASA 100mg/die, clopidogrel 300mg loading
dose, carvedilol 6.25mg, rosuvastatin 20mg/die, spironolacton
25mg/die and lisinopril 10mg/die was administered. Owing to the
persistence of angina and the hemodynamic instability, the
patient underwent emergency coronary angiography. The CRU-
SADE (Can Rapid risk stratiﬁcation of Unstable angina patients
Suppress ADverse outcomes with Early implementation of the
ACC/AHA Guidelines) bleeding score predicted a risk of in-hospital
major bleeding of 8.4%, corresponding to a moderate risk, with a
6.9% risk of death.6 Coronary angiography was performed from
the right femoral approach through a six French sheat and
Figure 1. (a) Coronary angiography of left anterior coronary artery (LAD) and left circumflex. Showing multiple severe stenosis on the LAD and
collateralization for the right coronary artery (RCA). Arrows indicate the stenosis treated by PCI and stenting. (b) Coronary angiography
showing the total chronic occlusion of the RCA. (c) LAD after crossing lesions with guidewire. (d) LAD after PCI and stenting.
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showed a severe coronary artery disease, with multiple critical
stenoses on the proximal and middle segment of left anterior
descending coronary artery (LAD), and a chronic total occlusion of
right coronary artery (Figures 1a and b). According to clinical and
instrumental data, we decided to perform a PCI on LAD. Before
PCI, a loading dose of Bivalirudin (0.75mg/kg) was administered
followed by an infusion of 1.75mg/Kg/h up to 2 h after procedure.
Then, a Launcher EBU guiding catheter (Medtronic, Minneapolis,
MN, USA) was advanced to the LAD, and, after predilation with
balloon catheter, a Genous-R-stent 3.0 33mm (OrbusNeich,
Fourt Lauderdale, FL, USA) was deployed, at 8.0 atm for 30 s,in
the proximal-medium portion of LAD. Finally, a non compliant
balloon catheter (3.0 15mm) was used to post dilate the stent
with good angiographic result (Figures 1c and d), ST resolution
and stopping of chest pain. Hemostasis of femoral artery was
obtained by Angioseal 6F. After PCI hematological advice has
been requested and bone marrow aspiration was consistent with
AML secondary to myelodisplastic syndrome, supporting our
initial suspect. The echocardiographic examination, performed
5 days after PCI, showed improved left ventricular global function
(EF 48%), and restored kinesis of the interventricular septum and
apex. Thus, 15 days after PCI plus stenting, patient stopped DAT
and started chemotherapy according to hematological advice.
At 30 days follow-up, no cardiovascular event or bleeding
complication was reported and the patient was discharged after
completing the ﬁrst cycle of chemotherapy. According to guide-
lines on myocardial revascularization, unfractionated heparin
(UFH) plus GP IIb/IIIa inhibitor therapy is the optimal pharmaco-
logical strategy for high-risk patients with NSTEMI undergoing
PCI.5 However,this strategy is associated with several
complications such as heparin-induced TP and increased risk of
bleedings.7 Bivalirudin alone, compared with heparin plus GPIIb/
IIIa inhibitors, has been proved to be safe and effective in high-risk
patients undergoing PCI. The Genous stent is a bio-engineered
coronary stent coated with Anti-hCD34-speciﬁc antibodies that,
capturing to the luminal stent struts circulating endothelial
progenitor cells CD-34þ from the peripheral blood, accelerates
vascular healing, thus, allowing a short DAT, particularly useful in
patients with contra-indication or impossibility to a long term DAT
(undeferrable surgery, oncological diseases, allergy or/and
intolerance to ASA and/or Thienopyridine, high bleeding risk).8
In the reported case, we adopted strategy of PCI with bivaluridin,
as pharmacological therapy, and stenting with the Genous stent
obtaining a good procedural and clinical success in the absence of
bleedings. Finally, the use of Genous stent, allowing the early DAT
discontinuation after PCI, gave to the patients the chance
to start the required therapy for AML. We have recently
reported that, in patients with contraindications to long-term
DAT due to severe comorbidities, allergy and/or intolerance to
antiplatelet therapies or major surgery requirements early after
PCI, the use of Genous stent is a safe and effective strategy
allowing early DAT discontinuation, 2 weeks, after PCI. Moreover,
we reported the use of pro-healing stent as a safe and effective
strategy in patients with severe hemophilia undergoing PCI
for NSTEMI.8–10
Taken together, these data suggest that in high-risk patients,
such as patients with AML and severe TP, a strategy based on
bivalirudin and Genous stent is efﬁcacious and safe in order to
achieve both ischemic protection and bleeding risk reduction.
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